Price
Target price
€1.65
€1.65
-0.960%
-0.016
-0.960%
€3.00
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Cardiol Therapeutics Inc. Stock
The price for the Cardiol Therapeutics Inc. stock decreased slightly today. Compared to yesterday there is a change of -€0.016 (-0.960%).
With 1 Sell predictions and 1 Buy predictions the community sentiment towards the Cardiol Therapeutics Inc. stock is not clear.
As a result the target price of 3 € shows a very positive potential of 81.6% compared to the current price of 1.65 € for Cardiol Therapeutics Inc..
Pros and Cons of Cardiol Therapeutics Inc. in the next few years
Pros
?
B****
?
G***** c******* t* c**********
?
S********** s********
Cons
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
News
Cardiol Therapeutics Announces Year-End 2023 Update on Operations
- Completed patient enrollment in the Phase II MAvERIC-Pilot study evaluating CardiolRx™ in patients with recurrent pericarditis, with topline results expected in Q2 2024
-
Cardiol Therapeutics Completes Patient Enrollment in its Phase II MAvERIC-Pilot Study Investigating CardiolRx™ for Recurrent Pericarditis
Topline Results Expected in Q2 2024
This is a Designated News Release.
Toronto, ON – February 21, 2024 – Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (“Cardiol” or the “Company”),
Cardiol Therapeutics Granted Orphan Drug Designation for its Lead Drug Candidate for the Treatment of Pericarditis
Designation Based on Pre-clinical Data and Initial Clinical Data from the Company’s MAvERIC-Pilot Phase II Study
This is a Designated News Release.
Toronto, ON – February 15, 2024 –